{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:53:03Z","timestamp":1777859583735,"version":"3.51.4"},"reference-count":6,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Ceftriaxone is a third-generation cephalosporin commonly used for treating bacteremia caused by gram-positive organisms such as\n                    <jats:italic>Streptococcus spp.<\/jats:italic>\n                    and gram-negative organisms such as Enterobacterales. The typical doses for treating bacteremia are either 1\u00a0gram or 2\u00a0grams daily. Despite its widespread use, there are limited data on the optimal treatment dose for bacteremia.\n                    <jats:bold>Methods:<\/jats:bold>\n                    This IRB-approved retrospective cohort study evaluated the difference in the clinical failure rate among patients who received 1\u00a0gram or 2\u00a0grams of ceftriaxone once daily for documented bacteremia. Clinical failure was defined as a composite of the following: antibiotic escalation, escalation to intensive care, and 30-day readmission due to an infectious cause. Adult patients admitted to Long Island Jewish (LIJ) Valley Stream, LIJ Forest Hills, or LIJ Medical Center in 2022 who received ceftriaxone were reviewed for inclusion. Patients were excluded if they received ceftriaxone for endocarditis or meningitis, had a positive blood culture with a ceftriaxone-resistant pathogen, or received ceftriaxone for less than 72\u00a0hours.\n                    <jats:bold>Results:<\/jats:bold>\n                    A total of 128 patients were included in this study. Approximately 46.9% of the participants received a 1\u00a0gram dose, while 53.2% received a 2\u00a0gram dose. 35.4% of patients in the 2\u00a0gram group experienced clinical failure compared to 21.7% in the 1\u00a0gram group (\n                    <jats:italic>P<\/jats:italic>\n                    = .08, OR 0.51; 95% CI 0.23-1.11).\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Our findings indicate that the primary outcome of clinical failure did not significantly differ between the 1\u00a0gram and 2\u00a0gram doses.\n                  <\/jats:p>","DOI":"10.1177\/08971900241313399","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T08:07:16Z","timestamp":1736582836000},"page":"425-429","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Retrospective Analysis of Ceftriaxone 1 Gram or 2 Grams for Bacteremia"],"prefix":"10.1177","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7682-0704","authenticated-orcid":false,"given":"Jae Hee","family":"Park","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Long Island Jewish Valley Stream, Valley Stream, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Critical Care, Department of Pharmacy, Long Island Jewish Valley Stream, Valley Stream, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Bain","sequence":"additional","affiliation":[{"name":"Internal Medicine, Department of Pharmacy, Long Island Jewish Valley Stream, Valley Stream, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bessma","family":"Hassani","sequence":"additional","affiliation":[{"name":"Infectious Disease &amp; Antimicrobial Stewardship, Department of Pharmacy, Long Island Jewish Valley Stream, Valley Stream, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1424-1908","authenticated-orcid":false,"given":"Christina","family":"Tang","sequence":"additional","affiliation":[{"name":"Emergency Medicine, Department of Pharmacy, Long Island Jewish Valley Stream, Valley Stream, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"key":"e_1_3_4_2_2","volume-title":"Ceftriaxone [Package Insert]","author":"Pfizer Inc","year":"2024","unstructured":"Pfizer Inc. Ceftriaxone [Package Insert]. New York, NY: Pfizer Inc.; 2024. Accessed June 6, 2024."},{"key":"e_1_3_4_3_2","unstructured":"Alhadad A Tehrani A Surio C Jeffres M. Clinical Outcomes of Ceftriaxone 1 Gram vs. 2 Gram Daily for the Treatment of Gram-Negative Enterobacteriaceae Bloodstream Infections. Denver CO: University of Colorado Anschutz Medical Campus Skaggs School of Pharmacy."},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4552-8"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/87551225221121252"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.760-766.2005"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/diseases8030027"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900241313399","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08971900241313399","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900241313399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:33:46Z","timestamp":1777509226000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08971900241313399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,11]]},"references-count":6,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/08971900241313399"],"URL":"https:\/\/doi.org\/10.1177\/08971900241313399","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,11]]}}}